Peter Reiss


Peter Reiss

  • Professor of Medicine, Department of Global Health, Amsterdam UMC, University of Amsterdam
  • Academic Staff
  • Director Stichting HIV Monitoring

Peter Reiss is Professor of Medicine at the Amsterdam UMC in Amsterdam, the Netherlands, where he holds a joint appointment in the Department of Global Health and the division of Infectious Diseases.

Peter Reiss has been Director of the Netherlands HIV Monitoring Foundation since February 2013. He also serves on the Scientific Advisory Boards of the Agence Nationale de Recherches sur de Sida et les hepatitis virales (ANRS) and the Swiss HIV Cohort Study, as well as on the Steering Committees of the D:A:D study, the Antiretroviral Therapy Cohort Collaboration and the EuroSida Study. In addition, Peter Reiss was until recently one of the four rotating scientific coordinators of EuroCoord.

Dr. Reiss is clinical HIV section editor for Antiviral Therapy and editorial board member of a number of other journals. He also served as President of the European Aids Clinical Society (EACS) from 2008-2012 and continues to serve on the EACS Governing Board. Until 2014 he served as the European and Central Asia regional representative on the Governing Council of the International AIDS Society (IAS), and he currently serves as local co-chair for the next International AIDS Conference to be held in Amsterdam in July 2018. His current research focuses primarily on the complications of HIV and HIV treatment, and more particularly in relation to aging.

View Peter’s publications (PubMed) 


Cross-sectional comparison of the prevalence of age-associated comorbidities and their risk factors between HIV-infected and uninfected individuals: the AGEhIV cohort study.
Schouten J, Wit FW, Stolte IG, Kootstra NA, van der Valk M, Geerlings SE, Prins M, Reiss P; AGEhIV Cohort Study Group..Clin Infect Dis. 2014 Dec 15;59(12):1787-97. doi: 10.1093/cid/ciu701. Epub 2014 Sep 2.PMID:25182245

Low bone mineral density in patients with well-suppressed HIV infection: association with body weight, smoking, and prior advanced HIV disease.
Kooij KW, Wit FW, Bisschop PH, Schouten J, Stolte IG, Prins M, van der Valk M, Prins JM, van Eck-Smit BL, Lips P, Reiss P; AGEhIV Cohort Study group..J Infect Dis. 2015 Feb 15;211(4):539-48. doi: 10.1093/infdis/jiu499. Epub 2014 Sep 1.PMID:25180239

Higher Prevalence of Hypertension in HIV-1-Infected Patients on Combination Antiretroviral Therapy Is Associated With Changes in Body Composition and Prior Stavudine Exposure.
van Zoest RA, Wit FW, Kooij KW, van der Valk M, Schouten J, Kootstra NA, Wiersinga WJ, Prins M, van den Born BJ, Reiss P; AGEhIV Cohort Study Group..Clin Infect Dis. 2016 Jul 15;63(2):205-13. doi: 10.1093/cid/ciw285. Epub 2016 May 3.PMID:27143668

Increased brain-predicted aging in treated HIV disease.
Cole JH, Underwood J, Caan MW, De Francesco D, van Zoest RA, Leech R, Wit FW, Portegies P, Geurtsen GJ, Schmand BA, Schim van der Loeff MF, Franceschi C, Sabin CA, Majoie CB, Winston A, Reiss P, Sharp DJ; COBRA collaboration..Neurology. 2017 Apr 4;88(14):1349-1357. doi: 10.1212/WNL.0000000000003790. Epub 2017 Mar 3.PMID:28258081

High Cellular Monocyte Activation in People Living With Human Immunodeficiency Virus on Combination Antiretroviral Therapy and Lifestyle-Matched Controls Is Associated With Greater Inflammation in Cerebrospinal Fluid.
Booiman T, Wit FW, Maurer I, De Francesco D, Sabin CA, Harskamp AM, Prins M, Garagnani P, Pirazzini C, Franceschi C, Fuchs D, Gisslén M, Winston A, Reiss P, Kootstra NA; Comorbidity in Relation to AIDS (COBRA) Collaboration .
Open Forum Infect Dis. 2017 May 25;4(3):ofx108. doi: 10.1093/ofid/ofx108. eCollection 2017 Summer. PMID: 28680905